Goldman Sachs Group Inc Contrafect Corp Transaction History

Goldman Sachs Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 May 14, 2024	BUY	$0.09 - $0.19 $1,505 - $3,178	16,730 New	16,730 $1,000
Q4 2022 Feb 13, 2023	BUY	$0.09 - $0.19 $1,505 - $3,178	16,730 New	16,730 $1,000
Q2 2022 Aug 15, 2022	SELL	$2.79 - $4.45 $1.14 Million - $1.81 Million	-407,031 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.26 - $3.84 $11,182 - $19,000	4,948 Added 1.23%	407,031 $1.49 Million
Q4 2021 Feb 14, 2022	SELL	$2.47 - $4.14 $435,505 - $729,956	-176,318 Reduced 30.48%	402,083 $1.06 Million

Q3 2021 Nov 10, 2021	BUY	$3.19 - $4.43 $1.85 Million - $2.56 Million	578,401 New	578,401 $2.34 Million

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.